Global Hub Where Science, Business, Talent & Capital Converge
The Leaders
We’ve Built Companies in the Arena, Not From the Sidelines.
SOSV NY’s General Partners Stephen Chambers, PhD and Deborah Zajac, and Chief Science Officer Sabriya Stukes, PhD, bring over three decades of company-building and investment experience across multiple venture cycles. Before Stephen was an investor, he was a founding scientist at Vertex Pharma, a biotech super-unicorn, contributing to drugs that reached FDA approval, IPO, and global commercialization. Deborah is a veteran venture capitalist who first spun out GE’s science into startups, then invested in startups across sectors and stages as she scaled a new type of venture capital firm to $1.5B AUM. Their firsthand experience helps founders scale faster, de-risk execution, and build companies that can exit.
Why Choose NY?
The World’s Financial Capital
New York isn’t just a place to invent. It’s where industries are shaped, regulated, financed, and built. Founders are surrounded by customers, capital, regulators, and acquirers in NY, accelerating the path from breakthrough science to scalable companies to months instead of years. This is powered by world-class research institutions, billions in NIH funding, the U.S.’s largest life sciences workforce and life sciences manufacturing, and one of the largest startup and venture capital ecosystems globally.
Now accepting applications
(By the way, we’re reviewing applications on a rolling basis)
Your First Investor Matters
Operator to Operator
Before becoming investors, we were scientists, CEOs, and operators building deep tech from scratch. We’ve raised capital, struggled with payroll, faced failed experiments, navigated the FDA, and delivered products to market. That operator DNA is embedded in SOSV NY. We pressure-test strategy early, align science with market reality, and accelerate you toward real milestones, regulatory validation, revenue, and scalable growth. As investors, we have shaped startups from launch to exit. We know the signals and guide you.
The Team
Inflect with Seasoned VCs
You don’t get 1:1 mentoring—you get 5 Partners in your meetings. It can be every day (if you want), not every other Friday. In our office, there are literally no walls between your desk and ours.
Alex Hall-Daniels
Selin Altinok, PhD
Madeline Behr
Parsa Amiri
Bethany Watson
Cassandra De Jesus
What We Invest In
If It’s Technically Hard & Commercially Real, We’re Interested.
We back visionaries harnessing biology and deep tech across disciplines, with a primary focus on breakthroughs with a scientific moat. We specialize in the transition from the lab to industrial reality, supporting innovations that demand rigorous validation and sophisticated commercialization strategies. Whether you are engineering living systems or pioneering new physical or computational frontiers, we invest in the radical innovation that defines the next generation of industry.
Therapeutics
From First Check to First-in-Human
SOSV NY is a hub for therapeutic companies, capitalizing on New York’s status as a global biomedical innovation center. Within five years we already have three companies in the clinic, with a rich pipeline following. The team has built significant expertise in guiding therapeutics through preclinical, regulatory, and initial clinical milestones.
Deep Tech Innovation Hub
Thrive in the Center of it All
Every day at SOSV NY partners host deep tech gatherings in our Biome event space, which is well known to founders, VCs, technologists and executives across the greater New York area. The flow of new and familiar faces enriches the day at SOSV NY, and deepens the SOSV ecosystem. Interested to learn more about the Biome?
How to Apply
-
01.
Apply online, and someone from our team will read your application shortly to see if we’re a good fit.
-
02.
If we’re interested in learning more, we’ll reach out for an interview (or more, if we really like you and your idea).
-
03.
After we’ve determined that your idea is revolutionary and game-changing, we’ll send an offer to join our next cohort.